OBJECTIVES: Statins are the cornerstone of cardiovascular disease prevention reducing individual cardiovascular risk by as much as 25% to 35%. One reason for interrupting statin therapy is statin-induced myopathy. Myopathy is a general term for muscular skeletal disease that can range from muscle pain to rhabdomyolysis. The incidence rate of statin-induced myopathies has been reported to range from 10% to 20%. The objective of the present study was to evaluate the economic value of a pharmacogenomic (PGx) test for the diagnosis of statin-induced myopathy. METHODS: We developed a Markov model to investigate the economic value of a PGx test to diagnose statin-induced myopathy from the perspective of the Ministry of Health. The model assumes that only patients who experienced muscular skeletal pain (MSP) are tested and that patients and physicians are fully compliant to the test results. For simplification purposes, we assumed that, without a PGx test, all patients experiencing MSP interrupt their statin. The cost of the PGx test is assumed at $250. RESULTS: The results of the model show that the PGx test is a dominant strategy with a perfect test and remains nearly cost neutral with an imperfect PGx test having 20% of false positive and false negative rates (i.e., incremental cost of $85) yielding an incremental cost-utility ratio (ICUR) of $451 per quality-adjusted life year (QALY). Deterministic sensitivity analyses show that the most influential model parameters are associated with statin efficacy. The results of the probabilistic sensitivity analysis show that at a willingness-to-pay of $5,850 per QALY, 90% of the model simulations favor the PGx test strategy. CONCLUSIONS: The model shows that a PGx test for the diagnosis of statin-induced myopathy in patients with MSP having ≤20% of false positive and false negative test results, is an optimal strategy at all accepted conventional willingness-to-pay ICUR thresholds.